Association Between Plasma Levels of ANGPTL3, 4, 8 and the Most Common Additional Cardiovascular Risk Factors in Patients with Hypertension

Abstract

Background ANGPTL3, 4 and 8 have been reported to be involved in the regulation of lipid and glucose metabolism. The aim of this study was to investigate the expression of ANGPTL3, 4, 8 in hypertensive patients with or without overweight/obesity, T2D, and hyperlipidemia, and the possible association between their expression and the status of the aforementioned comorbidities. Methods Plasma levels of ANGPTL3, 4, and 8 in 87 hospitalized patients with hypertension were measured using ELISA kits. Associations between circulating ANGPTLs levels and the most common additional cardiovascular risk factors were assessed using multivariate linear regression analyses. Pearson’s correlation analysis was used to examine the association between ANGPTLs and clinical parameters. Results In the context of hypertension, (1) although not statistically significant, circulating ANGPTL3 levels were higher in the overweight/obese group than in the normal weight group; (2) circulating levels of ANGPTL3 and ANGPTL8 were significantly lower in patients with T2D than in non-diabetic patients; (3) circulating ANGPTL3 levels were significantly higher in the hyperlipidemic group than in the non-hyperlipidemic group. ANGPTL3 was associated with T2D and hyperlipidemia status, whereas ANGPTL8 was independently associated with T2D status. In addition, circulating ANGPTL3 levels were positively correlated with TC, TG, LDL-C, HCY, and ANGPTL8, and circulating ANGPTL4 levels were positively correlated with UACR and BNP. Conclusion Changes in circulating ANGPTL3 and ANGPTL8 levels have been observed in hypertensive patients with the most common additional cardiovascular risk factors, suggesting a role in the common comorbidities of hypertension and cardiovascular disease. Hypertensive patients with overweight/obesity or hyperlipidemia may benefit from therapies targeting ANGPTL3.

Identification of novel prognostic targets in acute kidney injury using bioinformatics and next generation sequencing data analysis

“…BMI1 [245], CCL5 [246], GREM1 [247], ANGPTL3 [248], ARG2 [249], MSRA (methionine sulfoxidereductase A) [250], SNCA (synuclein alpha) [251], NOX4 [252], PFKFB2 [253], PDZK1 [254], SUCNR1 [255], LYVE1 [256], AZGP1 [257], ERBB4 [258] and PLAT (plasminogen activator, tissue type) [259] might serve as molecular markers for kidney fibrosis. BMI1 [260], IGF2 [261], IRF7 [262], CCL5 [263], ACTN3 [264], E2F1 [265], PF4 [266], TEAD4 [267], TBX4 [268], GREM1 [269], CYP11B2 [270], WNT3A [124], COMP (cartilage oligomeric matrix protein) [271], FLI1 [272], RAP1B [273], ANGPTL3 [274], CYP3A5 [275], HSD11B2 [276], HMGCS2 [277], AGXT2 [278], SLC22A12 [279], FGF1 [280], CRY1 [281], PPARGC1A [282], SLC19A3 [283], CYP2C8 [284], ACOX2 [285], SLC2A9 [286], MSRA (methionine sulfoxidereductase A) [287], VNN1 [288], EPHX2 [289], CROT (carnitine O-octanoyltransferase) [290], SCNN1B [291], NR4A3 [292], HSD17B7 [293], SLC22A2 [294], AQP2 [295], SLC2A2 [296], EGF (epidermal growth factor) [297], ANGPT1 [298], SLC26A4 [299], KL (klotho) [300], SCNN1G [301], PDZK1 [302], PTPRD (protein tyrosine phosphatase receptor type D) [303], ACE2 [304], FOLH1 [305], SUCNR1 [306], GLCE (glucuronic acid epimerase) [307], AQP3 [308], DPP4 [309], REN (renin) [310], TRPM6 [311], ABCB1 [312], MTTP (microsomal triglyceride transfer protein) [313], CALCRL (calcitonin receptor like receptor) [314], ENPEP (glutamylaminopept...…”

Emerging insights into the roles of ANGPTL8 beyond glucose and lipid metabolism

“…Circulating ANGPTL8 levels were significantly higher in hypertensive patients, as well as in mice and rats (Abu-Farha et al, 2018;Xu et al, 2023;Jiao et al, 2023). It is generally believed that this association is due to its role in LPL inhibition.…”

Metabolic syndrome: prospects for the use of angiopoetin-like proteins type 3 and 4 for the diagnosis of metabolic disorders

“…У пациентов с АГ, по данным F. Xu et al, циркулирующие уровни ANGPTL3 были значительно ниже у пациентов с СД2 (р < 0,001 по сравнению с пациентами с АГ без диабета) и значительно выше у пациентов с гиперлипидемией (р = 0,047 по сравнению с пациентами с АГ без гиперлипидемии), тогда как не было существенной разницы в уровнях ANGPTL4 внутри рассматриваемых групп (р = 0,80 и р = 0,36 соответственно). Обнаруженная связь циркулирующего ANGPTL3 с состоянием гиперлипидемии в контексте гипертензии, по мнению авторов, может быть использована в новых терапевтических стратегиях у пациентов с гипертонической болезнью с избыточной массой тела / ожирением или гиперлипидемией для снижения риска сердечно-сосудистых заболеваний [53].…”